Mazor Robotics (NASDAQ: MZOR) and Arch Therapeutics (OTCMKTS: ARTH) are small-cap medical companies, but what is the best stock? Let's compare the two companies based on the strength of their institutional ownership, dividends, recommendations of analysts, profitability, valuation, risk and profit.
This is an analysis of the current ratings and target prices of Mazor Robotics and Arch Therapeutics, as reported by MarketBeat.com.
|Selling Ratings||Hold Ratings||Purchase Ratings||Strong Buy Ratings||Rating score|
Mazor Robotics currently has a target price of $ 51.67, suggesting a potential downside of 11.38%. Arch Therapeutics has a consensus target price of $ 3.00, suggesting a potential upside of 669.23%. Given Arch Therapeutics' strongest consensus rating and likely ascending value, analysts clearly believe that Arch Therapeutics is more favorable than Mazor Robotics.
Volatility and Risk
Mazor Robotics has a beta of 1.32, indicating that the share price is 32% more volatile than the S & P 500. Comparatively, Arch Therapeutics has a beta of 0.83, indicating that the price of its shares is 17% less volatile than the S & P 500.
Evaluation and earnings
This table compares gross revenue, earnings per share (EPS) and valuation from Mazor Robotics and Arch Therapeutics.
|Gross Revenue||Price / Sales Ratio||net income||Earnings per share||Price / Profit ratio|
|Robotics Mazor||US $ 64.95 million||23.63||– US $ 12.41 million||(US $ 0.50)||-116.60|
|Arch Therapeutics||N / A||N / A||– US $ 7.78 million||($ 0.05)||-7.80|
Arch Therapeutics has lower revenue, but higher earnings than Mazor Robotics. Mazor Robotics is trading at a lower price-earnings ratio than Arch Therapeutics, indicating that it is currently the most affordable of the two stocks.
Insider & Institutional Ownership
22.6% of the shares of Mazor Robotics are held by institutional investors. Comparatively, 0.0% of the shares of Arch Therapeutics are held by institutional investors. Strong institutional ownership is an indication that hedge funds, grants, and large fund managers believe that a company will outperform the market in the long run.
This table compares the net margins of Mazor Robotics and Arch Therapeutics, return on equity and return on assets.
|Net Margins||Return on equity||Return on assets|
|Arch Therapeutics||N / A||-253.72%||-115.60%|
Arch Therapeutics outperforms Mazor Robotics on 7 of 12 factors compared between the two stocks.
Mazor Robotics Company Profile
Mazor Robotics Ltd., along with its subsidiaries, participates in the development, production and marketing of medical devices to support surgical procedures in the areas of orthopedics and neurosurgery in the United States and internationally. It acts in the field of computer assisted surgery that allows the use of surgical instruments with high precision and minimal invasiveness and that simplifies complex surgical procedures. The company's surgical robotic guidance systems and complementary products are used to conduct spinal and brain procedures accurately and safely. It also offers Mazor X, a rebirth system and its accessories are used in spine surgeries, including fusion, correction of spinal deformities, biopsy collection, tumor excision and cement increase. The company was formerly known as Mazor Surgical Technologies Ltd. and changed its name to Mazor Robotics Ltd. in 2010. Mazor Robotics Ltd. was founded in 2000 and is based in Caesarea, Israel.
Company Profile Arch Therapeutics
Arch Therapeutics, Inc., operates as a biotechnology company in the United States. The company develops products based on its technology to stop bleeding and control leaks, as well as offer other advantages during surgeries, trauma and interventional care. Its primary product is AC5 Devices, a synthetic biocompatible peptide that comprises naturally occurring amino acids to obtain hemostasis in minimally invasive and open surgical procedures. The company was founded in 2006 and is based in Framingham, Massachusetts.
Receive news and reviews for Mazor Robotics Daily – Enter your email address below to receive a concise daily summary of the latest Mazor Robotics analyst news and reviews from companies related to the FREE daily newsletter from MarketBeat.com.